Applicant, as named in the Orange Book
Apgdi
Part of Astellas Pharma
Company and ticker: cliffwatch mapping, checked against SEC EDGAR
Next listed expiry: Myrbetriq on 28 Mar 2030. 2 products with live protection, 0 without.
Products with listed protection
| Drug | Earliest generic entry |
|---|---|
| Myrbetriq NDA 202611 · 2 strengths mirabegron | 28 Mar 2030 patent |
| Myrbetriq Granules NDA 213801 mirabegron | 30 Sep 2036 patent |
Recent events
- Myrbetriq · Generic approved · ANDA 218543, MsnApproved 4 Nov 2025Detected 25 Oct 2026
- Myrbetriq · Generic approved · ANDA 219941, Deva Holding AsApproved 1 May 2026Detected 25 Oct 2026
- Myrbetriq Granules · First generic approved · ANDA 219323, Alkem Labs LtdApproved 20 Jan 2026Detected 25 Oct 2026
- Myrbetriq Granules · Generic approved · ANDA 219323, Alkem Labs LtdApproved 20 Jan 2026Detected 25 Oct 2026
- Myrbetriq · Generic approved · ANDA 219599, Creekwood PharmsApproved 7 Oct 2026Detected 25 Oct 2026